Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1549

Sort by

Sort Order Select

Journal Articles

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

Andrew W. Roberts, Freda K. Stevenson

Blood (2021) 138 (13): 1089.

https://doi.org/10.1182/blood.2021012674

Published: 2021

Journal Articles

How I treat pediatric acute myeloid leukemia

Jeffrey E. Rubnitz, Gertjan J. L. Kaspers

Blood (2021) 138 (12): 1009–1018.

https://doi.org/10.1182/blood.2021011694

Published: 2021

Journal Articles

CLL-IPI: valid in the era of oral inhibitors?

Nadine Kutsch

Blood (2021) 138 (2): 106–107.

https://doi.org/10.1182/blood.2021011937

Published: 2021

Journal Articles

How I treat warm autoimmune hemolytic anemia

Wilma Barcellini, Bruno Fattizzo

Blood (2021) 137 (10): 1283–1294.

https://doi.org/10.1182/blood.2019003808

Published: 2021

Journal Articles

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia

Blood (2021) 137 (10): 1377–1391.

https://doi.org/10.1182/blood.2020007897

Published: 2021

Includes: Supplemental data

Journal Articles

How I treat relapsed or refractory AML

Susan DeWolf, Martin S. Tallman

Blood (2020) 136 (9): 1023–1032.

https://doi.org/10.1182/blood.2019001982

Published: 2020

Journal Articles

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Blood (2020) 136 (4): 387–400.

https://doi.org/10.1182/blood.2019003267

Published: 2020

Includes: Supplemental data

Journal Articles

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Blood (2020) 135 (22): 1929–1945.

https://doi.org/10.1182/blood.2019003507

Published: 2020

Journal Articles

Long-term follow-up of mTOR inhibition for Erdheim-Chester disease

Francesco Pegoraro, Valerio Maniscalco, Francesco Peyronel, Pieter J. Westenend, Tadek R. Hendriksz, Rosa M. Roperto, Alessandro A. Palumbo, Elena Sieni, Paola Romagnani, Eric F. H. van Bommel, Augusto Vaglio

Blood (2020) 135 (22): 1994–1997.

https://doi.org/10.1182/blood.2019004478

Published: 2020

Includes: Supplemental data

Journal Articles

Management of ECD: the era of targeted therapies

Oussama Abla

Blood (2020) 135 (22): 1919–1920.

https://doi.org/10.1182/blood.2020005803

Published: 2020

Journal Articles

Erdheim-Chester disease

Julien Haroche, Fleur Cohen-Aubart, Zahir Amoura

Blood (2020) 135 (16): 1311–1318.

https://doi.org/10.1182/blood.2019002766

Published: 2020

Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach

Blood (2019) 134 (21): 1796–1801.

https://doi.org/10.1182/blood.2019001321

Published: 2019

Journal Articles

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

Samah Nassereddine, MD, Kimberley Doucette, MD MSc, Vanya Aggarwal, Richard Amdur, PhD, Imad A. Tabbara, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 2212.

https://doi.org/10.1182/blood-2019-124150

Published: 2019

Journal Articles

Hemostasis, Hematoma Expansion, and Outcomes after Intracerebral Hemorrhage

Paul F Lindholm, MD, Hau C. Kwaan, MD PhD, Andrew M Naidech, MDMSPH

Blood (2019) 134 (Supplement_1): 4886.

https://doi.org/10.1182/blood-2019-128370

Published: 2019

Journal Articles

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Michael S Broder, MD MSHS, Qiufei Ma, PhD, Tingjian Yan, PhD, Eunice Chang, PhD, Lamis K. Eldjerou, MD, Yanni Hao, PhD, David Kuzan, MD, Jie Zhang, PhD

Blood (2019) 134 (Supplement_1): 4719.

https://doi.org/10.1182/blood-2019-122587

Published: 2019

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling

Srividya Swaminathan, PhD, Line Dam Heftdal, MD, Daniel Liefwalker, PhD, Renumathy Dhanasekaran, MD, Anja Deutzmann, PhD, Crista Horton, BS, Adriane Mosley, BS, Mariola Liebersbach, BS, Andrew Gentles, PhD, Holden T. Maecker, PhD, Dean Felsher, MD PhD

Blood (2019) 134 (Supplement_1): 730.

https://doi.org/10.1182/blood-2019-122607

Published: 2019

Journal Articles

Notch1 mutation in B Chronic Lymphocytic Lymphocytes Induces Proliferation through Cell Cycle G1/S Phase-Specific Cyclin Overexpression

Ana M Hurtado López, Tzu Hua Chen-Liang, María Zurdo, Anna Puiggros, PhD, Andrea Gómez-Llonín, B.Sc., María-Dolores García-Malo, MD, Francisco José Ortuño, Vicente Vicente Garcia, MD PhD, Blanca Espinet, PhD, Andres Jerez

Blood (2019) 134 (Supplement_1): 851.

https://doi.org/10.1182/blood-2019-127960

Published: 2019

Journal Articles

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

Pierre-Edouard Debureaux, Bruno Cassinat, PharmD, PhD, Juliette Soret-Dulphy, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Pierre-Emmanuel Rautou, MD PhD, Aurelie Plessier, Dominique Valla, Stephane Giraudier, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 836.

https://doi.org/10.1182/blood-2019-123775

Published: 2019

Journal Articles

Application of RNA Sequencing Detects a Large Number of Novel Fusion Transcripts in Patients with AML and MDS

Anna Stengel, PhD, Rabia Shahswar, MD, Wencke Walter, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2019) 134 (Supplement_1): 887.

https://doi.org/10.1182/blood-2019-124310

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Introduction to a review series on small-molecule targeted therapies for lymphoid malignancies

How I treat pediatric acute myeloid leukemia

CLL-IPI: valid in the era of oral inhibitors?

How I treat warm autoimmune hemolytic anemia

Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1 -mutated acute myeloid leukemia

How I treat relapsed or refractory AML

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era

Long-term follow-up of mTOR inhibition for Erdheim-Chester disease

Management of ECD: the era of targeted therapies

Erdheim-Chester disease

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

Hemostasis, Hematoma Expansion, and Outcomes after Intracerebral Hemorrhage

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling

Notch1 mutation in B Chronic Lymphocytic Lymphocytes Induces Proliferation through Cell Cycle G1/S Phase-Specific Cyclin Overexpression

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

Application of RNA Sequencing Detects a Large Number of Novel Fusion Transcripts in Patients with AML and MDS

Email alerts

ASH Publications

American Society of Hematology